| Form | Liquid |
|---|---|
| Host Species | Human |
| Clonality | Monoclonal |
| Isotype | IgG4-IgG1, Lambda |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Concentration | 2.35mg/ml |
| Endotoxin Level | Please contact the lab for this information. |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Species Reactivity | Human |
| Target | OSMRB, IL-31R subunit beta, Oncostatin-M-specific receptor subunit beta, Interleukin-31 receptor subunit beta, IL-31RB, IL-31R-beta, OSMR, IL-31 receptor subunit beta |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Expression System | Mammalian Cells |
| Accession Number | Q99650 |
| Background | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash. • Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma., PMID:34087162 • Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease., PMID:28368383 • Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth., PMID:34380633 • Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology., PMID:26198770 • The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure., PMID:35163735 • Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts., PMID:38717842 • Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR., PMID:38569939 • AHNAK, regulated by the OSM/OSMR signaling, involved in the development of primary localized cutaneous amyloidosis., PMID:37100691 • Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma., PMID:24659184 • Targeting OSMR in glioma stem cells., PMID:28177884 |
| Alternative Names | KPL-716, 30C6(N73D), BIIB069, BIIB-069, 2243320-83-2 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |